Nasal hyperreactive disease is a common upper airway disease in clinic, with representations of allergic rhinitis (AR) and vasomotor rhinitis (VMR). Its pathogenesis is complicated. And the current treatment strategy is mainly to improve the symptoms, but not to be cured. Recent studies have found that transient receptor potential (TRP) ion channels may be the important targets for the treatment of nasal hyperreactive disease. Especially with the in-depth researches of transient receptor potential vanilloid 1 (TRPV1), it is found that TRPV1 plays an important role in the neuro-immune regulatory network to the development of nasal hyperreactive disease. Some drugs are effective in the treatment of nasal hyperreactive disease by targeting TRPV1, which shows a promising clinical transformation prospect of TRPV1. At present, there is a lack of systematic research on TRPV1 in nasal hyperreactive disease. Therefore, this article reviews the role of TRPV1 in nasal hyperreactive disease, in order to provide theoretical basis and new ideas for the treatment of nasal hyperreactive disease.